- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: C-7683 | compound 23 [WO2020264398]
Compound class: Synthetic organic
Comment: C7683 is an inhibitor of the novel oncology drug target Cbl-b. The chemical structure provided in the bioRxiv preprint  matches that claimed as 'compound No. 23' in Nurix Therapeutics' patent WO2020264398 . The closest structural match in PubChem is CID 155449671. Structural and biochemical analysis reveals that C7683 stabilises Cbl-b in an inactive conformation .
Cbl-b is an E3 ubiquitin protein ligase component of the ubiquitin proteasome pathway that negatively regulates T cell activation in the control of peripheral T cell tolerance [2-3], and can behave as a proto-oncogene. Pharmacological inhibition of this enzyme is predicted to offer anti-neoplastic potential.
Nurix have an orally bioavailable Cbl-b inhibitor with a related structure (named NX-1607) in clinical development for solid tumours.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|C-7683 | compound 23 [WO2020264398]
|GtoPdb PubChem SID
|RCSB PDB Ligand
|Search Google for chemical match using the InChIKey
|Search Google for chemicals with the same backbone
|UniChem Compound Search for chemical match using the InChIKey
|UniChem Connectivity Search for chemical match using the InChIKey